28
Participants
Start Date
December 31, 2011
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
Exelon Patch (rivastigmine transdermal system)
"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
Placebo Patches
The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
University of Pennsylvania, Ralston House, Philadelphia
University of Pennsylvania
OTHER